FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
|Articles|May 22, 2007
DDW: A Multimedia Special Report
Author(s)Stanton M Paddock
WASHINGTON -- This special report from Stanton M. Paddock, a MedPageToday contributing photographer, presents Ted Bader, M.D., of University of Oklahoma, discussing infection of Hepatitis C in Vietnam veterans.
Advertisement
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
Advertisement
Advertisement
Trending on Patient Care Online
1
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
2
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
3
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
4
FDA Approves Insulin Efsitora Alfa-Gobe for Adults With Type 2 Diabetes
5